Michele Bartoletti, MD, PhD

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Italy); IRCCS Humanitas Research Hospital, Rozzano (Italy), Italy

Disclosure(s): Advan pharma: Advisor/Consultant, Honoraria; Biomereux: Honoraria; Gilead: Advisor/Consultant, Honoraria; Infectopharma: Advisor/Consultant; Msd: Advisor/Consultant, Grant/Research Support, Honoraria; Pfizer: Honoraria

Poster(s):

• (P-1913) Characteristics, Clinical Management, and Outcomes of Leukemia, Lymphoma and Multiple Myeloma Patients Hospitalized with a Primary Diagnosis of COVID-19: Insights from Hospitals across the United States
  Saturday, October 19, 2024

  12:15 PM - 1:30 PM US PT

• (P-1973) Characteristics, Clinical Management, and Outcomes of Immunocompromised Patients Diagnosed with COVID-19 in the Outpatient Setting in France
  Saturday, October 19, 2024

  12:15 PM - 1:30 PM US PT

• (P-2021) How Have COVID-19 Treatment Guidelines and the Scientific Evidence Evolved throughout the Pandemic and Endemic Eras?
  Saturday, October 19, 2024

  12:15 PM - 1:30 PM US PT